1.

Mycobacterium
tuberculosis ..., ,
-

http://www.roche-appliedscience.ru/assets/files/seminar_20130416/08_ilina.pdf(2013)
2.
http://korrespondent.net/tech/217517-uchenye-rasshifrovaligenom-vozbuditelya-tuberkuleza(2007)
3.Migliori G.B., Loddenkemper R., Blasi F., Raviglione M.C. 125 years after Robert
Kochs discovery of the tubercle bacillus: the new XDR-TB threat. Is science
enough to tackle the epidemic? Eur. Respir J. 2007; 29 (3): 423-427.
http://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/WeltTBTag2007/WeltTBtag2007_E
ditorial-125YearsKochMigliori.pdf?__blob=publicationFile

4. Centers for Disease Control and Prevention. Emergence of Mycobacterium

tubercu$
losis with extensive resistance tosecond$line drugs$world$wide. Morbid. Mortal.
Wkly
Rep.2006; 55: 301-305.
5. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB
threat. Is science enough to tackle the epidemic?
G. B. Migliori 1 , R. Loddenkemper 2 , F. Blasi 3 and M. C. Raviglione
http://erj.ersjournals.com/content/29/3/423.full
References??????

Raviglione MC, Uplekar M. WHO's new Stop TB Strategy. Lancet 2006;367:952

955. CrossRefMedlineOrder article via InfotrieveWeb of Science
Sharma SK, Liu JJ. Progress of DOTS in global tuberculosis control. Lancet
2006;367:950952.
Stop TB Partnership and World Heath Organization. The Global Plan to Stop TB
20062015. Geneva, World Health Organization, 2006
Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International Standards
for Tuberculosis Care. Lancet Infect Dis 2006;6:710725. CrossRefMedlineOrder
article via InfotrieveWeb of Science
World Health Organization. Guidelines for the programmatic management of
drug-resistant Tuberculosis. WHO/HTM/TB/2006.361. Geneva, World Health
Organization, 2006

 Centers for Disease Control and Prevention. Emergence of Mycobacterium

tuberculosis with extensive resistance to second-line drugs-worldwide. MMWR Morb
Mortal Wkly Rep 2006;55:301305. MedlineOrder article via Infotrieve
World Health Organization. Extensively drug-resistant tuberculosis (XDR.TB):
recommendations for prevention and control. Weekly Epidemiol Record
2006;81:430432. MedlineOrder article via Infotrieve
The tuberculosis X factor. Lancet Infect Dis 2006;6:679 CrossRefMedlineOrder
article via InfotrieveWeb of Science
Masjedi MR, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2
years of surveillance in Iran. Clin Infect Dis 2006;43:841847. Abstract/FREE Full
Text
Dahle UR. Extensively drug resistant tuberculosis: beware patients lost to followup. BMJ 2006;333:705 FREE Full Text
Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a
cause of death in patients co-infected with tuberculosis and HIV in a rural area of
South Africa. Lancet 2006;368:15751580. CrossRefMedlineOrder article via
InfotrieveWeb of Science
Raviglione MC. XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis
2006;10:11851187. MedlineOrder article via InfotrieveWeb of Science
Migliori GB, Hopewell PC, Blasi F, Spanevello A, Raviglione MC. Improving the TB
case management: the International Standards for Tuberculosis Care. Eur Respir J
2006;28:14. FREE Full Text
3.GB Migliori, R Loddenkemper, F Blasi and MC Raviglione. 125 years after Robert
Kochs discovery of the tubercle bacillus: the new XDR-TB threat. Is science
enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
http://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/WeltTBTag2007/WeltTBtag2007_E
ditorial-125YearsKochMigliori.pdf?__blob=publicationFile
4.Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in
Italy resistant to all tested drugs. Euro Surveil. 2007; 12(20): pii=3194.
5.Migliori GB, Ortmann J, Girardi E et al. Extensively drug-resistant tuberculosis, Italy
and Germany. Emerging Infectious Diseases, 2007;13: 780-782.
6.Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drugresistant tuberculosis bacilli: super extensively drug-resistant tuberculosis of totally
drug-resistant strain in Iran. Chest 2009; 136: 420-425.
7.Zarir F Udwadia, Rohot A Amale, Kanchan K Ajbani, Camilla Rodrigues.
Correspondence: Totally Drug-Resistant Tuberculosis in India. Clin Infect Dis,
published online December 21, 2011 doi:10.1093/cid/cir889
http://cid.oxfordjournals.org/content/54/4/579.full
8.Katherine Rowland (13 January 2012). "Totally drug-resistant TB emerges in India"

http://www.nature.com/news/totally-drug-resistant-tb-emerges-in-india-1.9797
9.Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli:
Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in
Iran Ali Akbar Velayati, MD; Mohammad Reza Masjedi, MD; Parissa Farnia, PhD;
Payam Tabarsi, MD; Jalladein Ghanavi, MD; Abol Hassan ZiaZarifi, PhD; Sven Eric
Hoffner, MD http://journal.publications.chestnet.org/article.aspx?articleid=1089963
8.Times of India. New deadlier form of TB hits India. Jan 7, 2012.
9.World Health Organization. Policy guidance on drug susceptibility testing (DST) of
second-line anti-tuberculosis drugs. WHO/HTM/TB/2008.392
10.WHO. Guidelines for the programmatic management of drug-resistant
tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva,
Switzerland: WHO, 2008.
11.The Tuberculosis Coalition for Technical Assistance. International Standards of
Care. 2006. http://www.who.int/tb/publications/2006/istc_report_shortversion.pdf
(accessed 12 January 2012)
12.WHO. Guidelines for the programmatic management of drug-resistant
tuberculosis. 2011 Update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
13.Raviglione MC, Uplekar MW. WHOs new Stop TB Strategy. Lancet 2006; 367:
952-5.
14.Stop TB Partnership. The Global Plan to Stop TB 2011-2015: transforming the
fight towards elimination of tuberculosis. Geneva, World Health Organization, 2010
(WHO/HTM/STB/2010.2).
15.Nathanson E, Nunn P, Uplekar MW, Floyd K, Jaramillo E, Lnnroth K, Weil D, and
Raviglione M. MDR Tuberculosis Critical Steps for Prevention and Control. N Engl J
Med 2010; 363: 1050-8.
16.WHO. A ministerial meeting of high M/XDR-TB burden countries.
WHO/HTM/TB/2009.415. Geneva, Switzerland: WHO, 2009. (Accessed 12 January
2012)
17.WHO. 62nd World Health Assembly. Prevention and control of multidrug-resistant
tuberculosis and extensively drug-resistant tuberculosis. WHA62.15. 8th plenary
meeting, May 22, 2009. A62/VR/8.
http://www.who.int/tb/features_archive/wha62_15_tb_resolution/en/index.html.
(Accessed 12 January 2012)
18.WHO. Global Tuberculosis Control 2011. WHO/HTM/TB/2011.16. Geneva,
Switzerland: WHO, 2011.
19. Lancet. 2006 Nov 4;368(9547):1575-80.Extensively drug-resistant tuberculosis
as a cause of death in patients co-infected with tuberculosis and HIV in a rural area
of South Africa.Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U,
Zeller K, Andrews J, Friedland G. http://www.ncbi.nlm.nih.gov/pubmed/17084757

20. indian J Tuberc. 2010 Oct;57(4):180-91.Multidrug and extensively drug-resistant

TB (M/XDR-TB): problems and solutions.Prasad R.
http://www.ncbi.nlm.nih.gov/pubmed/21141336
21. MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.Plan to combat extensively
drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task
Force. http://www.ncbi.nlm.nih.gov/pubmed/19214162
22. The Lancet, Volume 372, Issue 9647, Pages 1403 - 1409, 18 October 2008
Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a
retrospective cohort study
Dr Salmaan Keshavjee MD Corresponding AuthorEmail Address, Irina Y Gelmanova
MD , Prof Paul E Farmer MD , Sergey P Mishustin MD etc.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61204-0/fulltext
23. The Lancet, Early Online Publication, 17 January 2014 Long-term outcomes of
patients with extensively drug-resistant tuberculosis in South Africa: a cohort study
Elize Pietersen MSSc , Elisa Ignatius MD , Elizabeth M Streicher PhD,etc
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62675-6/abstract
24. Oxford JournalsMedicine Clinical Infectious Diseases Volume 51, Issue 1Pp. 6-14
Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis:
Systematic Review and Meta-Analysis Karen R. Jacobson, Dylan B. Tierney1, Christie
Y. Jeon, Carole D. Mitnick, and Megan B. Murray (2010)
http://cid.oxfordjournals.org/content/51/1/6.long
25. References????????
Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium
tuberculosis with extensive resistance to second-line drugsworldwide, 20002004.
MMWR Morb Mortal Wkly Rep 2006;55:301-5.
Medline
World Health Organization. Countries that had reported at least one XDR-TB case
by end March 2009. http://www.who.int/tb/challenges/xdr/xdr_map_mar09.pdf.
Accessed 17 November 2009.
World Health Organization. Anti-tuberculosis drug resistance in the world, fourth
global report: the WHO/IUATLD Global Project on Anti- Tuberculosis Drug Resistance
Surveillance. Ebooks Corporation 2008. WorldCat.org entry.
http://www.worldcat.org/oclc/437123756&referer=brief_results. Accessed 17
November 2009.
Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drugresistant tuberculosis. Emerg Infect Dis 2007;13:380-7.
MedlineWeb of Science

 Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on
treatment outcomes in non-HIV-infected patients with multidrugresistant
tuberculosis. Clin Infect Dis 2007;45:1290-5.
Abstract/FREE Full Text
Andrews JR, Gandhi NR, Moll AP, et al. High mortality among patients with multidrug
and extensively drug-resistant tuberculosis in rural South Africa [abstract PS7204112]. Program and abstracts of the 38th Union World Conference Lung Health (Cape
Town, South Africa) 2007.
Search Google Scholar
Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the
extensively drug-resistant tuberculosis definition. Eur Respir J 2007;30:623-6.
Abstract/FREE Full Text
Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a
cause of death in patients co-infected with tuberculosis and HIV in a rural area of
South Africa. Lancet 2006;368:1575-80.
CrossRefMedlineWeb of Science
Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drugresistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet
2008;372:1403-9.
CrossRefMedlineWeb of Science
Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of
XDR-TB: a systematic review by TBNET. Eur Respir J 2009;33:871-81.
Abstract/FREE Full Text
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in
epidemiology: a proposal for reporting. JAMA 2000;283:2008-12.
Abstract/FREE Full Text
World Health Organization. Emergency update 2008. Geneva: World Health
Organization; 2008. Guidelines for the programmatic management of drug-resistant
tuberculosis.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials
1986;7:177-88.
CrossRefMedlineWeb of Science
Agresti A, Coull BA. Approximate is better than exact for interval estimation of
binomial proportions. Am Stat 1998;52:119-26.
CrossRef

 Cochran W. The combination of estimates from different experiments. Biometrics

1954;10:101-29.
CrossRefWeb of Science
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat
Med 2002;21:1539-58.
CrossRefMedlineWeb of Science
Statacorp. College Station, TX: Statacorp; 2007. Stata statistical software: release
10.
Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis
in California/ 19932006. Clin Infect Dis 2008;47:450-7.
Abstract/FREE Full Text
Blaas SH, Mutterlein R, Weig J, et al. Extensively drug resistant tuberculosis in a high
income country: a report of four unrelated cases. BMC Infect Dis 2008;8:60-7.
CrossRefMedline
Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis (TB) resistant to
fluoroquinolones and streptomycin but susceptible to second-line injection therapy
has a better prognosis than extensively drug-resistant TB. Clin Infect Dis
2009;48:e50-2.
Abstract/FREE Full Text
Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolidcontaining regimen for extensively drug-resistant tuberculosis. Chest 2008;134:18792.
Abstract/FREE Full Text
Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drugresistant
tuberculosis, Germany. Emerg Infect Dis 2008;14:1700-6.
CrossRefMedlineWeb of Science
Jeon DS, Kim DH, Kang HS, et al. Survival and predictors of outcomes in non-HIVinfected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis
2009;13:594-600.
MedlineWeb of Science
Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in
patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med
2008;178:1075-82.
Abstract/FREE Full Text
Kliiman K, Altraja A. Predictors of poor treatment outcome in highly drug-resistant
pulmonary tuberculosis. Eur Respir J 2009;33:1085-94.

Abstract/FREE Full Text

Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes for HIVuninfected patients
with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis
2008;47:496-502.
Abstract/FREE Full Text
Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drugresistant tuberculosis. N Engl J Med 2008;359:563-74.
CrossRefMedline
Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the
United States, 19932007. JAMA 2008;300:2153-60.
Abstract/FREE Full Text
World Health Organization. Geneva: World Health Organization; 2006. The Stop
TB strategy: building on and enhancing DOTS to meet the TB-related millenium
development goals.
Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant
pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Chest 2000;117:744-51.
Abstract/FREE Full Text
Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA.
Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium
tuberculosis selected in the laboratory and isolated from patients. Antimicrob
Agents Chemother 1995;39:1700-3.

Abstract/FREE Full Text

Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of
Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone
resistance mutations. Antimicrob Agents Chemother 1994;38:773-80.
Abstract/FREE Full Text
Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and
resistance. Lancet Infect Dis 2003;3:432-42.
CrossRefMedlineWeb of Science
Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and
ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and
pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents
Chemother 2007;51:576-82.
Abstract/FREE Full Text

 Kocagoz T, Hackbarth C, Unsal I, et al. Gyrase mutations in laboratoryselected,

fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob
Agents Chemother 1996;40:1768-74.
Abstract/FREE Full Text
Devasia RA, Blackman A, May C, et al. Fluoroquinolone resistance in
Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate
reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother
2009;63:1173-8.
Abstract/FREE Full Text
Rieder HL, Cauthen GM, Comstock GW, Snider DE. Epidemiology of tuberculosis in
the United States. Epidemiol Rev 1989;11:79-98.
FREE Full Text
Raviglione MC. New York: Informa Healthcare; 2009. Tuberculosis, fourth edition:
the essentials.
Search Google Scholar
Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug- resistant
tuberculosis management in resource-limited settings. Emerg Infect Dis
2006;12:1389-97.
MedlineWeb of Science
Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with
multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect
Dis 2009;9:153-61.
CrossRefMedlineWeb of Science
25. Susceptibility Testing of Extensively Drug-Resistant and PreExtensively Drug-Resistant Mycobacterium tuberculosis against
Levofloxacin, Linezolid, and Amoxicillin-Clavulanate
Imran Ahmed, Kauser Jabeen, Raunaq Inayat and Rumina Hasan
Antimicrob. Agents Chemother. (2013) 57 (6): 2522-2525
AbstractFull Text (HTML)Full Text (PDF)
http://aac.asm.org/content/57/6/2522.abstract
26. Oxford JournalsMedicine The Journal of Infectious Diseases Volume
207, Issue 1Pp. 1-3
Six Degrees of Separation: Use of Social Network Analysis to Better
Understand Outbreaks of Nosocomial Transmission of Extensively DrugResistant Tuberculosis Ashwin S. Dharmadhikari
http://jid.oxfordjournals.org/content/207/1/1.full(2012)

27. Eur Respir Rev (2011) 20 (120): 71-84 Update on tuberculosis: TB in

the early 21st century
D.W. Connell*, M. Berry*#, G. Cooke and O.M. Kon*
http://err.ersjournals.com/content/20/120/71.full
28. World Health Organization. Multidrug and Extensively Drug-Resistant
TB (M/XDR-TB): 2010 Global Report on Surveillance and Response.
WHO/ATM/TB2010.3. Geneva, World Health Organization, 2010.
29. European TB Pharmaceutical Management Conference TB Conference Europe
LogoFighting Drug-Resistant TB in the 21st Century: Novel Approaches to Improving
Access to anti-TB Medicines and Pharmaceutical Services 1st Conference on
Pharmaceutical Management for TB and M/XDR-TB for WHO European Region
Antalya, Turkey, 10 13 December, 2013
21- :

.

!!!!!!!!!!!!http://siapsprogram.org/events/european-tb-conference-2013/

30. Progress, challenges and Opportunities to fulfill the Consolidated Action Plan to
Prevent and Combat M/XDR-TB in the WHO European Region Dr Martin van den
Boom, MD, MSc PH
Technical Officer, TB and M/XDR.TB WHO Regional Office for Europe
1st Conference on Pharmaceutical Management for TB and M/XDRTB for WHO
European Region, Antalya, Turkey, 1013 December 2013
http://siapsprogram.org/wp-content/uploads/2013/04/Panel-1.1-Martin-ENG.pdf
30. Int J Tuberc Lung Dis. 2013 Feb;17(2):146-52. doi: 10.5588/ijtld.12.0017. Epub
2012 Dec 4
Compassionate use of and expanded access to new drugs for drug-resistant
tuberculosis.
Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, PyneMercier L, Keshavjee S, Varaine F; Research Excellence to Stop TB Resistance
(RESIST-TB); Critical Path to TB Drug Regimens' Access and Appropriate Use
Workgroup
http://www.ncbi.nlm.nih.gov/pubmed/23211610
References
1 .World Health Organization. Multidrug- and extensively drug-

resistant TB (M/XDR-TB): 2010 global report on surveillance

and response. WHO/HTM/TB/2010.3. Geneva, Switzerland:
WHO, 2010.
2. World Health Organization. Global tuberculosis report 2012.
WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
3. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes
among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153
161.
9 Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med
2008; 359: 563574.
10. Keshavjee S, Gelmanova I Y, Farmer P E, et al. Treatment of
extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 14031409.
11 Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B.
Treatment outcomes among patients with extensively drugresistant tuberculosis: systematic review and meta-analysis.
Clin Infect Dis 2010; 51: 614.
12 Mdecins Sans Frontires/Partners in Health/Treatment Action
Group. An evaluation of drug-resistant TB treatment scale-up.
MSF/PIH/TAF, 2011. http://69.7.74.112/uploadedFiles/DRTB_
Report_A4_Final.pdf Accessed August 2012.
13 World Health Organization, Stop TB Partnership. The Global
Plan to Stop TB: 20112015. Geneva, Switzerland: WHO, 2010.
http://www.stoptb.org/global/plan/ Accessed August 2012.
14 Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for
the treatment of tuberculosis: needs, challenges, promise, and
prospects for the future. J Infect Dis 2012; 205 (Suppl 2):

S241S249.
15 Working Group on New TB Drugs, Stop TB Partnership, World Health
Organization. TB drug pipeline. Geneva, Switzerland:WHO, 2012.
http://www.newtbdrugs.org/pipeline. php Accessed August 2012.
16. Institute of Medicine. Expanding access to investigational therapies for HIV infection and AIDS. Roundtable for the development of drugs and vaccines against AIDS. Washington DC,
USA: National Academy Press, 1991.
17.Vale J. Expanding expanded access: how the Food and Drug Administration can
achieve better access to experimental drugs for seriously ill patients. Georgetown
Law J 2008; 96: 21432175.
18.OBrien R J, Geiter L J, Lyle M A. Rifabutin (ansamycin LM427)
for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis 1990; 141: 821826.
19.World Health Organization. Guidelines for the programmatic
management of drug-resistant tuberculosis. WHO/HTM/TB/
2008.402. Geneva, Switzerland: WHO, 2008.
20. Pineda J A, Prez-Elas M J, Pea J M, Luque I, RodrguezAlcantara F; Fosamprenavir Expanded Access Program Group.
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials
2008; 9: 309313.
21.de Mendoza C, Martn-Carbonero L, Barreiro P, et al. Salvage
treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin
Trials 2002; 3: 304309.
22.Compassionate use and treatment IND programs. Crit Path
AIDS Proj 1996; 31: 4067.
23.Amorosa V, Tebas P. Is it time to rethink the expanded-access
programs for HIV infection? J Infect Dis 2007; 196: 974977.
24.European Medicines Agency. Questions and answers on the

compassionate use of medicines in the European Union. EMA/

72144/2006(rev). London, UK: EMA, 2010.
25.British Columbia Cancer Agency. Guidelines for expanded
access protocols. Vancouver, BC, Canada: BCCA Research
Ethics Board, 2005. http://www.bccancer.bc.ca/NR/rdonlyres/
3BDE5649-ACA6-40C3-B20E-FC09815C5D3F/9402/EAP
Guidelines2005Mar12.pdf Accessed August 2012.
26.Douglas N. Preapproval opportunities. Appl Clin Trials 2008;
June 1. http://www.appliedclinicaltrialsonline.com/applied
clinicaltrials/article/articleDetail.jsp?id=522052&pageID=
1&sk=&date=3 Accessed October 2012.
27.ODonnell M R, Padayatchi N, Master I, Osburn G, Horsburgh C R. Improved early results for patients with extensively
drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc
Lung Dis 2009; 13: 855861.
28.Dheda K, Shean K, Zumla A, et al. Early treatment outcomes
and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet
2010; 375: 17981807.
29.Moran M, Strub-Wourgaft N, Guzman J, Boulet P, Wu L,
Pecoul B. Registering new drugs for low-income countries: the
African challenge. PLoS Med 2011; 8: e1000411.
30.Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis:
critical steps for prevention and control. N Engl J Med 2010;
363: 10501058.
31.World Health Organization. Guidance on ethics of tuberculosis prevention, care and control. WHO/HTM/TB/2010.16.
Geneva, Switzerland: WHO, 2010.
32.Coleman C H, Jaramillo E, Reis A, Selgelid M. Guidance on

ethics of tuberculosis prevention, care and control. Geneva,

Switzerland: World Health Organization, 2010.
33.van Roey J, Haxaire M. The need to reform current drug registration processes to improve access to essential medicines in
developing countries. Pharm Med 2008; 22: 207213.
34.Ndomondo-Sigonda M, Ambali A. The African medicines regulatory harmonization initiative: rationale and benefits. Clin
Pharmacol Ther 2011; 89: 176179.
35. Multi drug and extensively drug-resistant TB (M/XDR-TB) management: Current
issues Clinical Epidemiology and Global Health Volume 1, Issue 3 , Pages 124-128,
December 2013 http://www.ceghonline.com/article/S2213-3984(13)000444/abstract
35. Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
Barbara Eker, Johannes Ortmann, Giovanni B. Migliori, Giovanni Sotgiu, Ralf
Muetterlein, Rosella Centis, Harald Hoffmann, Detlef Kirsten, Tom Schaberg, Sabine
Ruesch-Gerdes, Christoph LangeComments to Author , and for the German TBNET
Group
Emerging infectious diseases journal , Volume 14, Number 11November 2008
*http://wwwnc.cdc.gov/eid/content/14/11/contents.htm
*http://wwwnc.cdc.gov/eid/article/14/11/08-0729_article.htm
36. Extensively Drug-Resistant Tuberculosis / K. Dheda [et al.] // N. Engl. J. Med.
2008. Vol. 359,
27. P. 2390
37. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Masjedi
MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A,
Hoffner S. Clin Infect Dis. 2006 Oct 1;43(7):841-48.
https://olive.broadinstitute.org/projects/tb_iran
38. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super
extensively drug-resistant tuberculosis or totally drug-resistant strains in
Iran.Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE.
Chest. 2009 Aug;136(2):420-5
39. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular
level. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, Kuan HO,
Ghanavi J, Farnia P, Varahram M. Eur Respir J. 2009 Nov;34(5):1202-3.
40.The totally drug resistant tuberculosis (TDR-TB). Velayati AA, Farnia P, Masjedi
MR. Int J Clin Exp Med. 2013 Apr 12;6(4):307-9. .

41. Velayati AA, Farnia P, Merza MA, Zhavnerko GK, Tabarsi P, Titov LP, Ghanavei J,
Farnia P, Setare M, Poleschuyk NN, Owlia P, Sheikolslami M, Ranjbar R, Masjedi MR:
New insight into extremely drug-resistant tuberculosis: using atomic force
microscopy. Eur Respir J 2010; 36: 1490-3.
http://www.broadinstitute.org/search/google/extensively%20drug%20resistant%2C
%20XDR
42. Genome Analysis of Multi- and Extensively-Drug-Resistant Tuberculosis from
KwaZulu-Natal, South Africa (Thomas R. Ioerger mail,Sunwoo Koo,Eun-Gyu
No,Xiaohua Chen,Michelle H. Larsen,William R. Jacobs Jr.,Manormoney Pillay,A.
Willem Sturm,James C. Sacchettini)
Published: November 05, 2009 DOI: 10.1371/journal.pone.0007778
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007778
43. Multidrug and extensively drug-resistant tuberculosis management:
Evidences and controversies
R. Prasad, Lung India. 2012 Apr-Jun; 29(2): 154159.doi: 10.4103/0970-2113.95321
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354490/
44. New treatment options for multidrug-resistant tuberculosis.Field
SK1, Fisher D, Jarand JM, Cowie RL. Ther Adv Respir Dis. 2012 Oct;6(5):255-68. Epub
2012 Jul 4. http://www.ncbi.nlm.nih.gov/pubmed/22763676

45. Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis:

The National Institute of Allergy and Infectious Diseases Research
Agenda and Recommendations for Priority Research Anthony S.
Fauci and the NIAID Tuberculosis Working Groupa;Oxford
Journals,Medicine,The Journal of Infectious Diseases,Volume 197, Issue 11
Pp. 1493-1498.

46. Best practices in prevention, control and care for drug- resistant tuberculosis ;
World Health Organization2013
http://www.euro.who.int/__data/assets/pdf_file/0020/216650/Best-practices-inprevention,control-and-care-for-drugresistant-tuberculosis-Eng.pdf
47. Changing the tide Consolidated Action Plan to Prevent and Combat Multidrugand Extensively
Drug-resistant Tuberculosis in the WHO European Region 20112015Dr Hans Kluge
Special Representative of the Regional Director on M/XDR-TB Director, Division of
Health Systems and Public Health Dr Guenael Rodier Director, Division of
Communicable Diseases, HealthSecurity and Environment Dr Masoud Dara,
Programme Manager, TB/MDR-TB and team
http://www.euro.who.int/__data/assets/pdf_file/0004/150178/RC61_Kluge_etal_Tide_T
B.pdf